These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease. Reid TE; Kumar K; Wang XS Curr Top Med Chem; 2013; 13(11):1353-62. PubMed ID: 23675941 [TBL] [Abstract][Full Text] [Related]
4. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes. Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660 [TBL] [Abstract][Full Text] [Related]
5. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Huang XP; Setola V; Yadav PN; Allen JA; Rogan SC; Hanson BJ; Revankar C; Robers M; Doucette C; Roth BL Mol Pharmacol; 2009 Oct; 76(4):710-22. PubMed ID: 19570945 [TBL] [Abstract][Full Text] [Related]
7. Mechanism of subendocardial cell proliferation in the rat and relevance for understanding drug-induced valvular heart disease in humans. Fielden MR; Hassani M; Uppal H; Day-Lollini P; Button D; Martin RS; Garrido R; Liu X; Kolaja KL Exp Toxicol Pathol; 2010 Nov; 62(6):607-13. PubMed ID: 19781924 [TBL] [Abstract][Full Text] [Related]
8. The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease. Kekewska A; Hübner H; Gmeiner P; Pertz HH J Pharmacol Exp Ther; 2011 Jul; 338(1):381-91. PubMed ID: 21518772 [TBL] [Abstract][Full Text] [Related]
9. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Fitzgerald LW; Burn TC; Brown BS; Patterson JP; Corjay MH; Valentine PA; Sun JH; Link JR; Abbaszade I; Hollis JM; Largent BL; Hartig PR; Hollis GF; Meunier PC; Robichaud AJ; Robertson DW Mol Pharmacol; 2000 Jan; 57(1):75-81. PubMed ID: 10617681 [TBL] [Abstract][Full Text] [Related]
11. Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor. Setola V; Dukat M; Glennon RA; Roth BL Mol Pharmacol; 2005 Jul; 68(1):20-33. PubMed ID: 15831837 [TBL] [Abstract][Full Text] [Related]
12. Function and expression differences between ergot and non-ergot dopamine D2 agonists on heart valve interstitial cells. Oana F; Onozuka H; Tsuchioka A; Suzuki T; Tanaka N; Kaidoh K; Hoyano Y; Hiratochi M; Kikuchi S; Takehana Y; Shibata N J Heart Valve Dis; 2014 Mar; 23(2):246-52. PubMed ID: 25076559 [TBL] [Abstract][Full Text] [Related]
13. Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs. Hajjo R; Grulke CM; Golbraikh A; Setola V; Huang XP; Roth BL; Tropsha A J Med Chem; 2010 Nov; 53(21):7573-86. PubMed ID: 20958049 [TBL] [Abstract][Full Text] [Related]
19. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Schaerlinger B; Hickel P; Etienne N; Guesnier L; Maroteaux L Br J Pharmacol; 2003 Sep; 140(2):277-84. PubMed ID: 12970106 [TBL] [Abstract][Full Text] [Related]